See more : BankInvest – Danske Aktier KL (BAIDKAA.CO) Income Statement Analysis – Financial Results
Complete financial analysis of Equillium, Inc. (EQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Equillium, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- TDH Holdings, Inc. (PETZ) Income Statement Analysis – Financial Results
- United Communications Partners Inc. (UCPA) Income Statement Analysis – Financial Results
- Virtuoso Acquisition Corp. (VOSOW) Income Statement Analysis – Financial Results
- Redbox Entertainment Inc. (RDBXW) Income Statement Analysis – Financial Results
- Iep Invest, NV (IEP.BR) Income Statement Analysis – Financial Results
Equillium, Inc. (EQ)
About Equillium, Inc.
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 36.08M | 15.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 126.00K | 118.00K | 72.00K | 45.00K | 23.00K | 6.10K | 122.00 |
| Gross Profit | 35.96M | 15.64M | -72.00K | -45.00K | -23.00K | -6.10K | -122.00 |
| Gross Profit Ratio | 99.65% | 99.25% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 37.04M | 37.55M | 26.38M | 19.38M | 17.64M | 4.94M | 1.33M |
| General & Administrative | 13.57M | 17.24M | 11.41M | 10.16M | 9.09M | 3.67M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.57M | 17.24M | 11.41M | 10.16M | 9.09M | 3.67M | 378.21K |
| Other Expenses | 0.00 | -352.00K | -1.27M | -265.00K | 1.13M | -4.64M | 0.00 |
| Operating Expenses | 50.61M | 54.79M | 37.79M | 29.55M | 26.73M | 8.62M | 1.71M |
| Cost & Expenses | 50.61M | 54.79M | 37.79M | 29.55M | 26.73M | 8.62M | 1.71M |
| Interest Income | 2.33M | 420.00K | 57.00K | 476.00K | 1.39M | 339.62K | 0.00 |
| Interest Expense | 491.00K | 1.05M | 1.07M | 1.10M | 279.00K | 2.56M | 379.39K |
| Depreciation & Amortization | 126.00K | 118.00K | 72.00K | 45.00K | 23.00K | 6.10K | 122.00 |
| EBITDA | -12.14M | -61.26M | -37.91M | -28.67M | -25.30M | -10.69M | -1.88M |
| EBITDA Ratio | -33.64% | -101.39% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -14.52M | -62.08M | -37.79M | -29.55M | -26.73M | -8.62M | -1.71M |
| Operating Income Ratio | -40.24% | -393.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.77M | -352.00K | -1.27M | -265.00K | 1.13M | -4.64M | -549.82K |
| Income Before Tax | -12.76M | -62.43M | -39.05M | -29.81M | -25.60M | -13.25M | -2.26M |
| Income Before Tax Ratio | -35.35% | -396.14% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 580.00K | 45.28M | -72.00K | -45.00K | -23.00K | 140.51K | -2.00 |
| Net Income | -13.34M | -107.71M | -38.98M | -29.77M | -25.58M | -13.25M | -2.26M |
| Net Income Ratio | -36.96% | -683.46% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.38 | -3.19 | -1.35 | -1.46 | -1.47 | -1.09 | -0.13 |
| EPS Diluted | -0.38 | -3.19 | -1.35 | -1.46 | -1.47 | -1.09 | -0.13 |
| Weighted Avg Shares Out | 34.73M | 33.73M | 28.81M | 20.36M | 17.38M | 12.19M | 17.45M |
| Weighted Avg Shares Out (Dil) | 34.73M | 33.73M | 28.81M | 20.36M | 17.38M | 12.19M | 17.45M |
Equillium Announces Positive Interim Data of Itolizumab in the First-line Treatment of Acute Graft-Versus-Host Disease
Equillium to Present Data at the 2020 American College of Rheumatology Meeting Demonstrating CD6 Modulation Improves Kidney and Skin Pathology in Preclinical Models of Systemic Lupus Erythematosus
EQ Stock: 6 Things to Know about Biotech Company Equillium
What This FDA Update Means for Equillium's COVID-19 Study
Equillium Receives FDA Clearance of COVID-19 IND for Phase 3 Trial
The Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In $6.5B Deal, 2 IPOs
With Biotech Stocks, Investors Love the Thrill of the Chase
Southern California Bancorp Announces Results for the Second Quarter 2020
Zacks: Analysts Anticipate Equillium (NYSE:EQ) to Announce -$0.44 Earnings Per Share
20 Healthcare Stocks Moving In Thursday's Pre-Market Session
Source: https://incomestatements.info
Category: Stock Reports